רילרט 20 מג ישראל - עברית - Ministry of Health

רילרט 20 מג

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - טבליות מצופות פילם - eletriptan hydrobromide 24.242 mg - eletriptan

רילרט 40 מג ישראל - עברית - Ministry of Health

רילרט 40 מג

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - טבליות מצופות פילם - eletriptan hydrobromide 48.485 mg - eletriptan

רילרט 80 מג ישראל - עברית - Ministry of Health

רילרט 80 מג

pfizer pfe pharmaceuticals israel ltd - eletriptan hydrobromide - טבליות מצופות פילם - eletriptan hydrobromide 96.97 mg - eletriptan

פרימולוט-נור ישראל - עברית - Ministry of Health

פרימולוט-נור

bayer israel ltd - norethisterone acetate - טבליה - norethisterone acetate 5 mg - norethisterone - norethisterone - oral progestron for: dysfunctional bleeding, primary and secondary amenorrhea, premenstrual syndrome, timing of mensturation and endometriosis.

אובסטין ישראל - עברית - Ministry of Health

אובסטין

perrigo israel agencies ltd - estriol - קרם - estriol 0.1 % - estriol - estriol - for the treatment of vulvo-vaginal complaints related to estrogen deficiency.

טמבוקור 50 מג טבליות ישראל - עברית - Ministry of Health

טמבוקור 50 מג טבליות

megapharm ltd - flecainide acetate - טבליה - flecainide acetate 50 mg - flecainide - flecainide - serious sustained life threatening supraventricular arrhythmias that have not responded to other drugs. paroxysmal atrial fibrillation and atrial flutter

טמבוקור 100 מג טבליות ישראל - עברית - Ministry of Health

טמבוקור 100 מג טבליות

megapharm ltd - flecainide acetate - טבליה - flecainide acetate 100 mg - flecainide - flecainide - serious sustained life threatening ventricular arrhytmias that have not responsed to other drugs. paroxymal atrial flutter.

בלארה ישראל - עברית - Ministry of Health

בלארה

tec-o-pharm-libra ltd - chlormadinone acetate; ethinylestradiol - טבליות מצופות פילם - ethinylestradiol 0.03 mg; chlormadinone acetate 2 mg - etynodiol and estrogen - etynodiol and estrogen - oral hormonal contraceptive.

פרזיסטה 75 מג ישראל - עברית - Ministry of Health

פרזיסטה 75 מג

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 75 mg - darunavir - darunavir - adult patients : prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment -experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment -experienced adult patients .pediatric patients :prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv in pediatric patients 6 years of age and older. this indication is based on week 24 analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment -experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric the following points should be considered when ini

פרזיסטה 150 מג ישראל - עברית - Ministry of Health

פרזיסטה 150 מג

j-c health care ltd - darunavir as ethanolate - טבליות מצופות פילם - darunavir as ethanolate 150 mg - darunavir - darunavir - adult patients : prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of human immunodeficiency virus (hiv -1) infection. this indication is based on analyses of plasma hiv rna levels and cd4+ cell counts from 2 controlled phase 3 trials of 48 weeks duration in antiretroviral treatment - naive and treatment -experienced patients and 2 controlled phase 2 trials of 96 weeks duration in clinically advanced, treatment -experienced adult patients .pediatric patients :prezista, co-administered with ritonavir (prezista/rtv), and with other antiretroviral agents, is indicated for the treatment of hiv in pediatric patients 6 years of age and older. this indication is based on week 24 analyses of plasma hiv rna levels and cd4+ cell counts from an open-label phase 2 trial in antiretroviral treatment -experienced pediatric patients 6 to < 18 years of age. in treatment-experienced adult and pediatric the following points should be considered when ini